This is a single-arm, open-label, multicenter clinical trial to investigate the safety and
efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative
treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or
complete TURBT. Patients will receive perioperative treatment with tislelizumab in
combination with nab-paclitaxel every 3 weeks for 3 treatment cycles over 9 weeks followed by
radical cystectomy or complete TURBT.
Muscle Invasive Bladder Cancer Urothelial Carcinoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.